Proteomics

Dataset Information

0

Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis

ABSTRACT: Non-alcoholic fatty liver disease is now considered the most common form of chronic liver disease. It is a complex metabolic disease that silently progresses into non-alcoholic steatohepatitis (NASH). In fact, NASH is the tipping point for pericellular fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Despite being a complex metabolic disease, identification of the metabolic readout that functions in metabolic pathway perpetuation for HCC progression from NASH is still incompletely understood. With the aid of LC MS/MS this study unveiled the metabolic fingerprint of NASH and HCC-NASH patients and it illustrates a detailed map for the most predominant reprogrammed metabolic pathways that target HCC development from NASH. https://doi.org/10.3390/ijms24010210

INSTRUMENT(S): TripleTOF 5600+

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Sameh Magdeldin  

PROVIDER: MSV000088003 | MassIVE | Thu Aug 19 06:51:00 BST 2021

REPOSITORIES: MassIVE

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1
altmetric image

Publications

Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis.

Ahmed Eman A EA   El-Derany Marwa O MO   Anwar Ali Mostafa AM   Saied Essa M EM   Magdeldin Sameh S  

International journal of molecular sciences 20221222 1

With the rising incidence of hepatocellular carcinoma (HCC) from non-alcoholic steatohepatitis (NASH), identifying new metabolic readouts that function in metabolic pathway perpetuation is still a demand. The study aimed to compare the metabolic signature between NASH and NASH-HCC patients to explore novel reprogrammed metabolic pathways that might modulate cancer progression in NASH patients. NASH and NASH-HCC patients were recruited and screened for metabolomics, and isotope-labeled lipidomics  ...[more]

Similar Datasets

Metabolomics GNPS - Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
2021-08-19 | MSV000088003 | GNPS
Proteomics Discovering biomarkers for non-alcoholic steatohepatitis pa-tients with and without hepatocellular carcinoma using fecal metaproteomics
2022-10-13 | PXD034175 | Pride
Transcriptomics Microarray analysis among non-alcoholic fatty liver, non-alcoholic steatohepatitis, and type 2 diabetes mellitus rats
2015-01-23 | E-GEOD-65220 | biostudies-arrayexpress
Transcriptomics Post-transplant (non-alcoholic steatohepatitis) NASH compared with transplanted normal controls
2022-05-09 | E-MTAB-11688 | biostudies-arrayexpress
Transcriptomics Hepatic transcriptomic changes during non-alcoholic steatohepatitis (NASH)-associated liver carcinogenesis in mice
2016-06-22 | E-GEOD-83596 | biostudies-arrayexpress
Transcriptomics Tid1 Deficiency Disrupting Mitochondria to Drive NASH-Dependent Hepatocellular Carcinoma Progression
2022-06-02 | E-MTAB-9973 | biostudies-arrayexpress
Proteomics Comprehensive PTP and proteome profiling from human liver tissues
2024-09-24 | PXD046940 | Pride
Transcriptomics Steatohepatitis progresses to cancer via immunosuppression of HCC directed CD8+ T cells
2017-09-08 | GSE90497 | GEO
Proteomics Liver epithelial cell-specific loss of mTOR aggravates tumor development in a murine model of nonalcoholic steatohepatitis related hepatocellular carcinoma
2023-11-15 | PXD039944 | Pride
Transcriptomics NCOA5 haploinsufficiency in myeloid cells sufficiently causes non-alcoholic steatohepatitis and hepatocellular carcinoma
2023-09-12 | GSE192554 | GEO